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Pregnancy and Infection
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Before the advent of antibiotic agents, pregnancy was a recognized risk factor for severe 
complications of pneumococcal pneumonia, including death.1 The influenza pandemic of 
2009 provided a more recent reminder that certain infections may disproportionately affect 
pregnant women. Are pregnant women at increased risk for acquiring infections? Are 
pregnant women with infection at increased risk for severe disease? During pregnancy, 
several mechanical and pathophysiological changes occur (e.g., a decrease in respiratory 
volumes and urinary stasis due to an enlarging uterus), and immune adaptations are required 
to accommodate the fetus. In this article, we review and synthesize new knowledge about 
the severity of and susceptibility to infections in pregnant women. We focus on the 
infections for which there is evidence of increased severity or susceptibility during 
pregnancy that is not fully explained by mechanical or anatomical changes, and we discuss 
these infections in light of new findings on immunologic changes during pregnancy.
PREGNANCY AND SEVERITY OF INFECTION
As compared with nonpregnant women, pregnant women are more severely affected by 
infections with some organisms, including influenza virus, hepatitis E virus (HEV), herpes 
simplex virus (HSV), and malaria parasites. The evidence is more limited for organisms that 
cause coccidioidomycosis, measles, smallpox, and varicella (Table 1). The threshold for 
diagnostic evaluation, as well as hospitalization and treatment, may be lower for pregnant 
women than for other patients, and this factor may bias some of the reports of increased 
disease severity.
INFLUENZA
Pregnant women are at increased risk for severe illness from influenza virus infection. 
Cardiopulmonary adaptive changes occurring during pregnancy, such as increased heart rate 
and stroke volume and reduced pulmonary residual capacity, may increase the risk of 
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hypoxemia and contribute to the increased severity. During the pandemic of 1918, maternal 
mortality was 27% (50% when influenza was complicated by pneumonia), and during the 
pandemic of 1957, 50% of deaths among reproductive-age women occurred among those 
who were pregnant.2 During the 2009 H1N1 influenza A pandemic, pregnant women were 
generally at increased risk for severe disease, including disease leading to hospitalization, 
admission to an intensive care unit, or death, as compared with nonpregnant women and the 
general population.3 In the United States, 5% of all deaths from pandemic influenza were 
among pregnant women, although pregnant women represent only about 1% of the U.S. 
population.4 Higher rates of hospital admission and medical encounters for pregnant women 
with confirmed or suspected influenza, as compared with the general population, and a 
greater severity of disease during late pregnancy were also found in interpandemic 
periods.5-7 During the 2009 H1N1 pandemic, as well as during interpandemic periods, 
women in the third trimester of pregnancy were at increased risk for severe disease (e.g., 
disease requiring admission to an intensive care unit or resulting in death), as compared with 
women in an earlier stage of pregnancy.4,6,8
HEV INFECTION
Infection with HEV is also more severe in pregnant women, with high mortality during the 
third trimester. In areas in which HEV infection is highly endemic (India, Southeast Asia, 
the Middle East, and Africa), it can be a major cause of maternal death and fetal loss. The 
pathophysiological basis of this increased mortality is not well understood.
In a review of all consecutive cases of acute liver failure from 1989 to 1996 in a region of 
India in which HEV infection is endemic, 49 of 83 women of childbearing age with acute 
liver failure were pregnant (33 in their third trimester). In 47 of these pregnant women, the 
liver failure was due to HEV infection.9 In a case series from India, 33 to 43% of pregnant 
women with HEV infection had severe disease or infection that led to fulminant hepatic 
failure.10 A review indicated that the case fatality rate among pregnant women with HEV 
infection is between 15% and 25%, as compared with a range of 0.5 to 4% in the population 
overall.11 Among 220 consecutive pregnant women presenting with jaundice caused by 
acute viral hepatitis, fulminant hepatic failure and death were more common among women 
with HEV infection than among those without HEV infection (relative risk of fulminant 
hepatic failure, 2.7; relative risk of death, 6.0).12
HSV INFECTION
Pregnant women with primary HSV infection have an increased risk of dissemination and 
hepatitis (an otherwise rare complication in immunocompetent adults), particularly during 
the third trimester. To date, 27 cases of HSV hepatitis during pregnancy have been 
reported.13 After patients with immunosuppression, pregnant women are the largest group of 
adults with disseminated HSV infection; in one review, the mean gestational age at 
presentation was 31 weeks, and the case fatality rate was 39% for both mothers and 
neonates.14 Other reviews have confirmed a high burden of HSV hepatitis among pregnant 
women15,16; however, data on the incidence of primary HSV infection among pregnant 
women are limited. Recurrences of genital HSV infection increase in frequency during 
Kourtis et al. Page 2













pregnancy,17 although the clinical characteristics of recurrent genital HSV infection are 
similar in pregnant women and nonpregnant women.
MALARIA
The severity of (and susceptibility to) Plasmodium falciparum malaria is determined by the 
level of immunity, which depends mainly on the intensity and stability of malaria 
transmission. In areas of low or unstable transmission, infected women become 
symptomatic, and, if untreated, the infection can progress rapidly to complications, with a 
high case fatality rate. In three districts in India, 23% or more of maternal deaths between 
2004 and 2006 were attributable to malaria, which was the most common cause of maternal 
death during pregnancy.18 Pregnant women have a risk of severe malaria that is three times 
as high as that among nonpregnant women; a median maternal mortality of 39% has been 
reported in studies in the Asia–Pacific region. Maternal death also has been reported in 
association with P. vivax infection.18
In areas of high transmission, most women harboring parasites do not present with 
symptoms. It was thought that, in such areas, cases of severe or fatal malaria during 
pregnancy were rare. However, the numbers of maternal deaths from malaria in sub-Saharan 
Africa may have been underestimated, and malaria during pregnancy may be an important 
direct cause of maternal complications and death.19,20 Of pregnant women who are 
symptomatic, the majority are women having their first pregnancy; women who have been 
pregnant more than once and who live in areas where malaria is highly endemic are less 
likely to present with clinical signs or symptoms of malaria, even if they have high parasite 
loads.20,21 The predominant theory to explain this phenomenon is that P. falciparum 
parasites accumulate selectively in the placenta, and particular anti-genic variants interact 
with syncytiotrophoblastic chondroitin sulfate A.22 Women have a malaria episode caused 
by chondroitin sulfate A–binding parasites during their first pregnancy because they lack 
immunity to antigenic variants presented by these strains (even though they may be immune 
to other antigenic variants of parasites that bind endothelial receptors from previous 
infections) and are thus highly susceptible to the new infection.
COCCIDIOIDOMYCOSIS
Several reports and case series have suggested that pregnancy is a risk factor for the 
development of severe and disseminated coccidioidomycosis, particularly during the third 
trimester and the immediate postpartum period, with an estimated rate of 7.7 to 11 cases per 
10,000 pregnancies.23-25 However, the rate of disease during pregnancy was much lower 
than expected in a large 1988 survey of records from three delivery centers in Tucson, 
Arizona, covering more than 47,000 deliveries.26 During the 1993 epidemic in Kern County, 
California, only 32 cases were identified among pregnant women, a lower number than 
expected; disseminated disease occurred in 3 of these cases, with no maternal deaths,27 
which suggested that many pregnant women have asymptomatic or clinically mild disease. 
Taken together, these data suggest that the incidence of coccidioidomycosis is decreasing 
and that pregnant women may not be at increased risk for dissemination.
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Early studies postulated that pregnancy, particularly in the third trimester, is a risk factor for 
severe varicella. These studies involved mostly case reports or small case series.28-30 In a 
1990 review of 34 published cases of varicella pneumonia, mortality among pregnant 
women was 35%,28 higher than that among nonpregnant adults, reported as 11.4% in 
another study.31 Paryani and Arvin reported a varicella pneumonia rate of 9%, with one 
death among 43 pregnant women with varicella.30 A review of reports published from 1965 
to 1989 on varicella pneumonia in adults showed that of 99 cases, 46 were in women; 28 of 
these women were pregnant (21 in the third trimester). This suggested an increased rate of 
varicella pneumonia during pregnancy; however, mortality among pregnant women (10%) 
was not higher than that among men and non-pregnant women.29 Other studies do not 
support the idea that illness due to varicella is more severe during pregnancy. In a New York 
City survey for the period from 1957 to 1964, only 1 of 144 women with varicella died.32 In 
a study from Britain and Germany, in which 1373 women with varicella were followed 
during pregnancy, no maternal deaths were reported.33
PREGNANCY AND SUSCEPTIBILITY TO INFECTION
In contrast to the rather strong evidence for increased severity of certain infections among 
pregnant women, the evidence regarding initial susceptibility is weaker. The evidence for 
increased susceptibility during pregnancy is most credible for infections with organisms 
such as P. falciparum and Listeria monocytogenes, both of which have tropism for the 
placenta; evidence is more limited for human immunodeficiency virus type 1 infection 
(Table 1).
MALARIA
The harmful effects of malaria (mainly due to P. falciparum) during pregnancy — maternal 
anemia, low birth weight, and preterm birth — have long been recognized.19 In areas of 
stable endemic transmission (e.g., sub-Saharan Africa), up to 25% of pregnant women have 
acute infection, leading to placental malaria34; this frequency is higher than that among 
nonpregnant women.35,36 In several studies in Africa and Asia, the prevalence of malarial 
parasitemia was found to be higher among pregnant females than among nonpregnant 
females 15 to 45 years of age.18,37,38 P. falciparum is the only species associated with 
placental sequestration, which is believed to be the cause of many of the manifestations of P. 
falciparum disease during pregnancy. Many studies have shown decreasing susceptibility to 
malaria with increasing parity,37-39 probably as a result of acquisition of immunity to 
parasites expressing pregnancy-specific variant surface antigens.19 This association is most 
pronounced in areas where malaria is highly endemic.20 Young maternal age may be an 
additional and independent risk factor for malaria during pregnancy. The third trimester of 
gestation has been associated with the highest risk of clinical malaria in some studies40 but 
not others.39 However, maternal parasitemia, placental parasite burden, and episodes of 
clinical malaria may be expressions of disease severity rather than of initial susceptibility in 
areas with a high prevalence of malaria.
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Limited data suggest that P. vivax infections also are more severe during pregnancy.18 These 
data, however, are difficult to interpret because most areas where P. vivax is the 
predominant cause of malaria have low or unstable transmission and therefore increased 
disease severity in all parity groups.41 Accumulation of P. vivax in the placenta has not been 
reported.42
LISTERIOSIS
Primarily a foodborne pathogen, listeria can contaminate a variety of raw foods, such as 
uncooked meats and vegetables, unpasteurized milk, and soft cheeses. Infection may be 
asymptomatic or may be manifested as an influenza-like illness; severe infection is rare 
during pregnancy, and no maternal deaths due to listeriosis have been reported among 
pregnant women who are hospitalized.43 L. monocytogenes infections most commonly occur 
during the third trimester and seem to be rare earlier in pregnancy.44 However, listeria has a 
predilection for the placenta and fetus, and, depending on the stage of pregnancy, listeriosis 
can lead to pregnancy loss, stillbirth, preterm birth, or serious neonatal disease. Active, 
population-based surveillance showed that 17% of 762 listeriosis cases reported in 10 U.S. 
sites between 2004 and 2009 were in pregnant women.45 Hispanic women seemed to be 
particularly at risk.45-47 It has been estimated that invasive listeriosis during pregnancy is 13 
times to more than 100 times as frequent as in the general population.45,46,48 However, in 
one study, surveillance data indicated that more than 50% of listeriosis cases during 
pregnancy were associated with a neonatal case,45 which suggests that neonatal disease 
leads to recognition of listeria infections during pregnancy in a substantial proportion of 
cases and may therefore bias estimates of pregnancy-conferred risk.
EVOLVING CONCEPTS OF IMMUNOLOGIC ALTERATIONS DURING 
PREGNANCY
Immunologic alterations during pregnancy may help explain the altered severity of and 
susceptibility to infectious diseases during pregnancy. As pregnancy progresses, hormone 
levels change dramatically and are considerably higher than at any other time.49 The 
interplay between sex hormones and the immune system is complex and multifactorial, and 
it affects many organ systems (Fig. 1). In humans, estradiol can enhance several aspects of 
innate immunity and both cell-mediated and humoral adaptive immune responses.51,52 In 
general, low estradiol concentrations promote CD4+ type 1 helper T-cell (Th1) responses 
and cell-mediated immunity, and high estradiol concentrations augment CD4+ type 2 helper 
T-cell (Th2) responses and humoral immunity.52 Progesterone can suppress the maternal 
immune response and alter the balance between Th1 and Th2 responses.49,53,54 Increasing 
estrogen and progesterone concentrations with advancing pregnancy lead to a reversible 
thymic involution. The mechanisms of estrogen and progesterone modulation of individual 
components of the immune system have been extensively studied in vitro but not in humans. 
There is evidence that aspects of innate immunity (phagocytic activity, α-defensin 
expression, and numbers of neutrophils, monocytes, and dendritic cells) are maintained or 
enhanced during pregnancy, particularly during the second and third trimesters.50,55 
Conversely, the number of CD3+ T lymphocytes (both CD4+ and CD8+) decrease during 
pregnancy56,57 as do Th1 and Th2 responses to mitogenic or antigenic lymphocyte 
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stimulation.55,58 However, there is limited information on the longitudinal trends of such 
alterations during pregnancy. Levels of several cytokines are altered: levels of interferon-γ, 
monocyte chemoattractant protein 1, and eotaxin are decreased in most pregnant women, 
whereas tumor necrosis factor α, interleukin-10, and granulocyte colony-stimulating factor 
levels rise.50 In general, levels of inflammatory cytokines are reduced, whereas levels of 
cytokines that induce phagocytic-cell recruitment or activity increase; these alterations do 
not necessarily follow a clear Th1 or Th2 phenotype.50 Regulatory T cells become more 
numerous.59
Several theories have been proposed to explain the immunologic alterations that occur 
during pregnancy. It was initially thought that pregnancy confers general 
immunosuppression to ensure tolerance of the semiallogeneic fetus.60 However, data 
indicating that fetus-specific cytotoxic T-cell responses can be generated during pregnancy 
without loss of the fetus,61 as well as data from studies of pregnant mice showing normal 
memory T-cell development after lymphocytic choriomeningitis virus infection,62 contradict 
the idea of systemic immunosuppression during pregnancy. Adequate immunologic 
responses to vaccination in pregnant women have been demonstrated in several studies and 
for several pathogens.63-66
The fact that pregnant women do not seem, on the basis of epidemiologic evidence, to be 
more susceptible to infections in general also contradicts this theory. A more recent theory 
proposed a shift from Th1 to Th2 immunity during pregnancy.67 Th2 cells stimulate B 
lymphocytes, increase antibody production, and suppress the cytotoxic T-lymphocyte 
response, decreasing the robustness of cell-mediated immunity. A shift to Th2 immunity is 
postulated to be responsible for altered responses to respiratory viral infections or 
autoantigens during pregnancy and could explain the increased severity of infections such as 
influenza or coccidioidomycosis, in which cell-mediated immunity is important.5,50,68
Elucidation of the immunologic alterations and adaptations that occur during pregnancy 
suggests that older concepts of pregnancy as a state of systemic immunosuppression are 
oversimplified. A more useful model may be the view of pregnancy as a modulated 
immunologic condition, not a state of immunosuppression.50 Decreases in adaptive 
immunity seen in later stages of pregnancy are consistent with the observed increase in the 
severity of certain infectious diseases during later pregnancy. Decreases in the numbers and 
function of CD4+, CD8+, and natural killer cells could affect antiviral, antifungal, or 
antiparasitic responses and delay clearance of the offending microorganism. However, the 
increases in innate immunity observed during pregnancy may help to prevent acquisition of 
infection and thus explain the absence of increased susceptibility to infections.
Furthermore, the placenta is an active immunologic site, capable of interacting with and 
responding to pathogens. The placental tropism of specific pathogens (e.g., listeria or P. 
falciparum) affects the susceptibility to and severity of certain infectious diseases during 
pregnancy, as well as pregnancy outcomes.54 Placental infection that elicits the production 
of inflammatory cytokines may activate the maternal immune system and lead to placental 
damage and miscarriage or preterm labor.69 Although a viral infection of the placenta that 
triggers a mild inflammatory response may not terminate the pregnancy, it can activate the 
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maternal immune system or that of the fetus, potentially promoting an inflammatory 
response that may lead to long-term neurodevelopmental or other sequelae,70 including 
diseases in adulthood,54 in the offspring.
FUTURE DIRECTIONS
The evidence of increased susceptibility of pregnant women to infection is rather weak; to 
adequately address this question, studies need to include nonpregnant age-matched controls, 
long prospective follow-up periods, and large samples. Even though pregnant women do not 
seem to be more susceptible than nonpregnant women to initial infection in general, 
immunologic alterations with advancing pregnancy may impair pathogen clearance, 
resulting in an increased severity of disease caused by some pathogens. Increased disease 
severity may also be due to other physiological changes of pregnancy (e.g., decreased lung 
capacity, urinary stasis, and changes in blood flow). There are many unanswered questions 
regarding the immunologic changes that occur as pregnancy progresses and the interplay of 
infection, pregnancy, and the fetus and placenta. The less detrimental effect of malaria in 
multiparous than in primiparous women could provide insights into disease pathogenesis 
during pregnancy that could be expanded to other infections, as well as to concepts of 
autoimmunity in general.
Given the hormonal shifts during pregnancy and the resultant effects on the immune system, 
efforts to reduce the pathogenesis of infectious and other diseases by modulating the 
hormonal environment locally or systemically warrant consideration. Approaches that boost 
pathogen-specific immunity or particular components of the immune system (e.g., 
alterations in certain cytokines and in regulatory T-cell subsets) may provide new 
prophylactic and therapeutic pathways. Interfering with the special interactions between 
some pathogens and the placenta may also offer a potential strategy for prophylaxis or 
therapy. Vaccination before and during pregnancy, which has proved safe and effective for a 
number of infectious agents, could one day be expanded to include vaccines against other 
relevant pathogens, such as HSV, HEV, and malaria parasites. The beneficial effects of 
maternal vaccination may not be limited to the mother but, by reducing fetal and placental 
inflammation, may also provide long-term benefits for the child. The education of pregnant 
women about prevention of infections and the early identification and appropriate treatment 
of infectious diseases during pregnancy remain important strategies for protecting maternal 
and infant health.
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Figure 1. Changes in Hormone Levels and Immune-System Characteristics during Pregnancy
As pregnancy advances, T-cell activity, natural killer cell activity, and possibly B-cell 
activity are reduced, whereas α-defensin levels and monocyte, dendritic-cell, and 
polymorphonuclear-cell activity are increased.49,50 The severity of some infections 
(particularly influenza, malaria, hepatitis E, and herpes simplex virus hepatitis and 
dissemination) increases with advancing pregnancy.
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Table 1
Infections Associated with Increased Susceptibility or Severity among Pregnant Women, and Relevant 
Clinical Guidance, According to the Strength of the Evidence for an Association.
Infection Increased Susceptibility Increased Severity Prevention Strategies Management Strategies*
Stronger evidence
Influenza No Yes Influenza vaccination; 
antiviral prophylactic 
medication for selected 
patients
Early identification; early 
antiviral therapy; supportive 
care
Hepatitis E virus 
infection
No Yes Sanitation programs High index of clinical 
suspicion; supportive care
Herpes simplex virus 
infection (dissemination 
with primary infection)
No Yes Protection from sexually 
transmitted infections 
during pregnancy
High index of clinical 
suspicion; antiviral therapy; 
supportive care; care of the 
newborn
Malaria (mainly due to 
Plasmodium falciparum)
Yes Yes Intermittent preventive 
therapy; insecticide-treated 
bed nets (for areas where 
malaria is endemic); 
appropriate prophylaxis 
(for travelers)
Early identification; appropriate 
antimalarial therapy; supportive 
care
Listeriosis Yes No Dietary guidance Early identification; appropriate 
anti-microbial therapy; care of 
the newborn
More limited evidence
Measles No Yes Vaccination High index of clinical 
suspicion; supportive care





Yes No Consistent and correct 
condom use; protection 




Varicella No Yes Vaccination Appropriate antiviral therapy; 
supportive care
Coccidioidomycosis No Yes No proven methods of 
prevention
Early identification; appropriate 
antifungal therapy
*
Infections for which there should be a higher or very high index of clinical suspicion are those that must be considered by the clinician despite 
being rare diagnoses in some areas.
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